NeurAxis, Inc. (NRXS)
:NRXS
Want to see NRXS full AI Analyst Report?
NRXS Stock Chart & Stats
$7.22
-$0.04(-1.54%)
At close: 4:00 PM EST
$7.22
-$0.04(-1.54%)
Day’s Range― - ―
52-Week Range$2.20 - $9.33
Previous CloseN/A
Volume9.85K
Average Volume (3M)55.04K
Market Cap
$92.02M
Enterprise Value$84.49M
Total Cash (Recent Filing)$7.08M
Total Debt (Recent Filing)$169.52K
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Sep 17, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.80
Shares Outstanding12,384,405
10 Day Avg. Volume34,967
30 Day Avg. Volume55,039
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)12.13
Price to Sales (P/S)11.55
P/FCF Ratio-6.38
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue19.73
Enterprise Value/Gross Profit23.21
Enterprise Value/Ebitda-11.84
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.56
Revenue Forecast (FY)$9.55M
Bulls Say, Bears Say
Bulls Say
High Gross Margins And Rising ASPSustained ~85%+ gross margins and rising average selling price indicate strong unit economics and favorable payer pricing. These durable margins mean incremental revenue largely flows to the margin line, improving scalability as volumes grow and supporting longer‑term profitability once fixed costs are absorbed.
Strengthening Reimbursement InfrastructureAdoption of a Category 1 CPT code and reported coverage of ~101M lives create a lasting backbone for reimbursement. This structural change reduces billing friction, supports broader provider adoption over months, and underpins sustainable revenue expansion if payer medical policy and prior‑auth rates continue improving.
Low Leverage And Improved Equity PositionVery low leverage and a return to positive equity materially lower solvency risk and provide financial flexibility. This durable balance sheet strength allows the company to fund commercialization, pursue strategic trials, and absorb variability without heavy interest burdens that could otherwise constrain operational execution.
Bears Say
Persistent Negative Operating Cash FlowConsistent negative operating and free cash flow shows the business is still consuming capital rather than generating it. That structural cash burn requires ongoing external financing or material revenue ramp to sustain operations and limits runway, creating execution risk over the next several quarters.
Adult Expansion Requires Large RCTReaching broad adult reimbursement depends on a large randomized trial, which is time‑consuming and capital intensive. This entrenched evidentiary requirement delays access to a major addressable market, forces resource tradeoffs, and limits near‑term revenue diversification and scale.
Large Revenue Gap To Cash‑flow BreakevenBreakeven requiring roughly $15M of revenue—about 2.5x current annualized levels—creates a substantial structural hurdle. Achieving that growth depends on consistent payer adoption, higher prior‑auth approvals, and deeper usage across concentrated accounts, making profitability contingent on multi‑quarter execution.
NeurAxis, Inc. News
NRXS FAQ
What was NeurAxis, Inc.’s price range in the past 12 months?
NeurAxis, Inc. lowest stock price was $2.20 and its highest was $9.33 in the past 12 months.
What is NeurAxis, Inc.’s market cap?
NeurAxis, Inc.’s market cap is $92.02M.
When is NeurAxis, Inc.’s upcoming earnings report date?
NeurAxis, Inc.’s upcoming earnings report date is Sep 17, 2026 which is in 117 days.
How were NeurAxis, Inc.’s earnings last quarter?
NeurAxis, Inc. released its earnings results on May 12, 2026. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.19 by $0.01.
Is NeurAxis, Inc. overvalued?
According to Wall Street analysts NeurAxis, Inc.’s price is currently Overvalued.
Does NeurAxis, Inc. pay dividends?
NeurAxis, Inc. does not currently pay dividends.
What is NeurAxis, Inc.’s EPS estimate?
NeurAxis, Inc.’s EPS estimate is -0.17.
How many shares outstanding does NeurAxis, Inc. have?
NeurAxis, Inc. has 12,384,405 shares outstanding.
What happened to NeurAxis, Inc.’s price movement after its last earnings report?
NeurAxis, Inc. reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.19. Following the earnings report the stock price went up 1.472%.
Which hedge fund is a major shareholder of NeurAxis, Inc.?
Currently, no hedge funds are holding shares in NRXS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NeurAxis, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
― (―)
― (―)
Insider Transactions
Bought Shares
Worth $32.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 10.1%
Last 30 Days ▲ 10.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
17.07%
12-Months-Change
Fundamentals
Return on Equity
-185.74%
Trailing 12-Months
Asset Growth
188.66%
Trailing 12-Months
Company Description
NeurAxis, Inc.
NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
NRXS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented clear early commercial progress: strong sequential and year-over-year growth, higher ASP and gross margins, improving KPIs, and early VA traction. However, substantial challenges remain—incomplete and uneven payer coverage, modest prior authorization approvals, continued operating losses, an upcoming sizable non-cash stock charge, and a large revenue gap to reach cash-flow breakeven. Management’s tone was optimistic and execution-focused, but the company remains dependent on accelerating payer policy adoption and deepening usage within priority accounts.View all NRXS earnings summariesNRXS Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Ownership Overview
10.97% Insiders
1.43% Mutual Funds
10.29% Other Institutional Investors
75.49% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---